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Considering the pH dependent chemical stability of anticancer drug methotrexate (MTX), the present
communication reports a new approach for intercalation of the same in a nanoceramic vehicle,
magnesium aluminium layered double hydroxide (LDH), by ex situ anion exchange method at pH 7.00,
using 0.3 M ammonium acetate solution for dissolution of the drug. This simple method ensures
maximum stability of the drug at the above said pH, with no degradation byproduct (e.g., N10-methyl folic
acid formed due to alkaline hydrolysis) under the given experimental conditions, compared to the similar
approach, using 0.1 M sodium hydroxide solution, reported in our earlier work. Importantly, the above
method leads to an enhanced drug loading of 32.3 wt%, compared to our previous reports. The
cumulative release proﬁle of MTX from LDH–MTX formulation in phosphate buﬀer saline (PBS) at pH 7.4
exhibited burst release initially which was taken care of by imparting a unique coating of poly(D,L-lactide-
co-glycolide, PLGA) on the LDH–MTX nanostructure that reduces the toxicity due to local accumulation.
Hence, the superiority of the above for use in cancer chemotherapy, over the conventional drug–polymer
system has been established w.r.t the drug release proﬁle and a possible hypothesis of the same has been
suggested. The half maximal inhibitory concentration (IC50) of the MTX drug used in this study has been
determined and the same has been used to estimate the time dependent (24, 48, 72 and 96 h) eﬃcacy of
the MTX loaded samples with/without polymer coating, on human colon tumour cells (HCT-116).Introduction
The versatility of methotrexate in diﬀerent treatment proce-
dures is well known,1–3 although it was originally developed and
continued to be used in chemotherapy, either alone or in
combination with other agents.4 Despite a plethora of new
drugs being used in the rst line treatment of cancer chemo-
therapy, methotrexate still remains a popular choice of drug for
the treatment of osteosarcoma, head and neck and breast
cancer. Most clinicians prescribe high-dose MTX (HDMTX)
($500 mg m2), used for central nervous system (CNS)
prophylaxis in patients with high-risk lymphoma and for the
treatment of osteosarcoma. The main toxicities of HDMTX are
elevated serum transaminase levels and renal insuﬃciency,
which can delay drug clearance.5,6 To overcome these secondary
toxicities, this drug basically is administered via intravenous
route in cycles within a single day, which is extremely painful
and unacceptable for a patient. Hence, controlled releaseLaboratory, 196, Raja S.C. Mullick Road,
jui@cgcri.res.in; Fax: +91-33-24730957;
Jadavpur University, Jadavpur, Kolkata,
tion (ESI) available. See DOI:
94delivery of the drug for an extended period of time is desirable
that aids in reduction of the dosage frequency and the systemic
toxicity. Further, chemical instability of the active component of
the drug leads to substantial lowering of the quantity of the
therapeutic agent in the dosage.7 pH is one of the most
important factors aﬀecting the stability of a drug that in turn is
a major criterion in determining its suitability for a particular
application, as above.8 At alkaline pH range, N10-methylfolic
acid is the degradation byproduct of MTX, by alkaline hydro-
lysis reaction.9,10 Hence, it is customary to develop “pH-Rate
proles” for drugs to determine the pH at which they are
most susceptible to degradation and then formulate at a
diﬀerent pH along with the use of buﬀers to minimize degra-
dation.11 Considering this, in the present report, we have used a
neutral medium, 0.3 M ammonium acetate of pH 7.00 for the
rst time, for dissolution of MTX, that aids to retain the pH
dependent chemical stability of the pH sensitive drug so that no
degradation by product, as above is formed and an enhanced
drug entrapment eﬃciency is obtained.
In the rational design and evaluation of new dosage forms for
drugs, a current approach encapsulates the chemically unstable,
pH sensitive drug, methotrexate, in a delivery matrix that reduces
the toxicity of the active pharmaceutical ingredient, when
administered via intravenous route, and takes care of the pH
sensitivity, as well. In this, a range of delivery matrices areThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinecommercially available that are mostly polymers and have their
intrinsic problems.12 Among the matrices in use other than
polymers, recently, a ceramic based nanoparticle known as
layered double hydroxide (LDH) has received much attention in
drug and gene delivery.13–15 They are a class of natural
and synthetic mixed metal hydroxides, anion exchanging
clay-like materials, having chemical composition:
[M1x
2+Mx
3+(OH)2]
+(An)x/n$mH2O, consists of brucite-like layers
containing hydroxides of metal cations M2+ and M3+ and possess
exchangeable anions, An and a variable number of water mole-
cules in interlayer space.16 Due to anion exchange properties of
LDH, many pharmaceutically active compounds, e.g., NSAIDs,
antineoplastic agents with an anionic counterpart, e.g., ibuprofen,
diclofenac, indomethacin, ampicillin, 5-urouracil, methotrexate
etc. have been intercalated into LDH brucite-like layers17–23 and
study on their sustained and controlled release, alongwith
reducing systemic toxicity of the drug have been reported.24–26
Despite the chemical instability of the MTX drug at alkaline pH
(>8.0) conditions, a number of research groups have used 0.1 M
sodium hydroxide solution for dissolution of the drug followed by
its intercalation/insertion within the LDH layers.
In this regard, no reports could be obtained that examines
the chemical stability of the intercalated drug and its eﬀect in
turn on the drug entrapment eﬃciency, under the said pH
conditions. Further, LDH–MTX system leads to the release of
the drug within a period of 24 h only which does not meet the
requisite criteria of the chemotherapeutic agents that might
eﬀectively reduce the dosage frequency, toxicity and enhance
patient compliance as well.
In view of the above, the present work reports the synthesis
of LDH by simple co precipitation route and intercalation of the
anionic counterpart of the anticancer drug methotrexate into
the LDH interlayer by ex situ anion exchange technique, using
0.3 M ammonium acetate solution for MTX dissolution, at pH
7.00, at which the drug has maximum stability.9,10,27 This
exhibits enhanced drug loading (32.3 wt%) of the LDH–MTX
system compared to our earlier results of 13.1 wt%. Hence, the
superiority of ammonium acetate solution at pH 7.00,
compared to sodium hydroxide solution at pH 8.5, for retention
of pH dependent chemical stability of MTX during intercalation
of the same by anion exchange process, has been
demonstrated.28,29
The initial burst release and the local toxicity due to accu-
mulation of the drug has been taken care by imparting a coating
of poly(D,L-lactide-co-glycolide) (PLGA, 50 : 50) on the LDH–MTX
nanohybrid by double emulsion (W1/O/W2)–solvent evaporation
technique for the rst time, to the best of our knowledge. The
initial burst release (upto 2 h) of MTX drug that leads to dose
dumping at the site, could be arrested by seven times approxi-
mately for the PLGA coated LDH–MTX compared to LDH–MTX
alone. Analogous to PLGA–LDH–MTX, the PLGA–MTX coun-
terpart, without LDH, was developed by single emulsion tech-
nique (O/W), using same amount of polymer. Signicantly, the
PLGA–MTX system exhibited complete release (99.9%) of MTX
by a period of 5 days, compared to the LDH incorporated system
(PLGA–LDH–MTX) that showed an extended release (99.5%) of
MTX upto a period of 10 days, demonstrated by a schematicThis journal is © The Royal Society of Chemistry 2015hypothesis. This extended release phenomenon of the PLGA–
LDH–MTX for a period of 10 days helps to minimize the dosage
frequency (via intravenous route in cycles within a single day) of
HDMTX in cancer treatment, thereby, helps to get rid of the
painful procedure of chemotherapy, alongwith its side eﬀects
and thus enhances patient compliance to a great extent. The
nanoparticles (pristine/drug loaded/PLGA coated) and the
PLGA–MTX system have been characterized using infrared
spectrophotometry, scanning electron microscopy, dynamic
laser scattering and thermogravimetric analysis-diﬀerential
thermal analysis and scanning calorimetry. The drug loading,
in vitro release and pH dependent degradation studies have
been carried out in PBS medium at pH 7.4, using high perfor-
mance liquid chromatograph (HPLC). Based on the half
maximal inhibitory concentration (IC50) of MTX drug, the time
dependent (24, 48, 72 and 96 h) cell viability assay of the MTX
loaded samples with/without polymer coating, on HCT-116 cells
exhibited around six times higher eﬃcacy for PLGA–LDH–MTX
system compared to bare MTX drug, in a period of 96 h.Experimental section
Materials
Methotrexate (molecular weight, 454.50 g mol1) was obtained
as a gi sample fromM/s Naprod Life Sciences, Mumbai, India.
Magnesium nitrate hexahydrate, Mg(NO3)2$6H2O, aluminum
nitrate nonahydrate, Al(NO3)3$9H2O, sodium hydroxide, NaOH
and ammonium acetate, CH3COONH4 were purchased from M/
s Sigma Aldrich, Bangalore, India. The polymer used in this
work, poly(D,L-lactide-co-glycolide) (PLGA), with a copolymer
ratio of D,L-lactide to glycolide of 50 : 50 (molecular weight in
the range, 24 000–38 000 g mol1) (M/s Boehringer Ingelheim
Pharma Gmbh & Co., Germany). The emulsier poly(vinyl
alcohol, PVA) and the solvent dichloromethane (DCM) were
purchased from M/s Sigma Aldrich, St. Louis, MO, USA.
Deionised and decarbonated ultrapure water (Millipore, specic
resistivity 18.2 MU) was used in all the syntheses as above and
the chemicals utilized in this study were used as received
without further purication. The nitrogen gas used for
synthesis and characterization in the present work is XL grade
having percentage purity, 99.999%.Preparation of the pristine LDH
32 mmol of Mg(NO3)2$6H2O and 16 mmol of Al(NO3)3$9H2O
were dissolved in 500 ml decarbonated water maintained at
40 C with stirring under a stream of nitrogen (XL grade, %
purity, 99.999) gas. The pH of the resulting mixed metal solu-
tion was adjusted to 11.3 with 0.5 M of NaOH solution to get
pristine LDH suspension that in turn was aged in the mother
liquor for 24 h at room temperature under a nitrogen gas
blanket, centrifuged (Heal Force, Neofuge 15R, China) at
9500 rpm for 5 min at 4 C to separate the precipitate. The
precipitate was washed several times with decarbonated water,
freeze dried (EYEL4, FDU2200, Japan, at 82 C and 20 Pa
pressure) to get ne, free owing nanocrystalline pristine LDH,
denoted as sample A.RSC Adv., 2015, 5, 39482–39494 | 39483
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View Article OnlinePreparation of the LDH–MTX nanohybrid by ex situ anion
exchange technique
In ammonium acetate solution. A 100 ml solution of meth-
otrexate (0.2% w/v) in 0.3 M ammonium acetate (pH 7.00) was
added to 50 ml of aqueous suspension of sample A. The mixture
was stirred (@1100 rpm) under nitrogen gas blanket for 48 h in
a light protected condition at room temperature, followed by
separation of the precipitate by centrifugation@9500 rpm for
8–10 min and washing several times with decarbonated water to
remove the unbound drug. Next, the drug loaded nanohybrid
formulation (LDH–MTX) was freeze dried and was named as
sample B.
In sodium hydroxide solution. In this, a solution (100 ml) of
methotrexate (0.2% w/v) in 0.1 M sodium hydroxide (pH 8.5)
was added to 50 ml aqueous suspension of sample A, and the
rest of the procedure is same as above, nally, the drug loaded
nanohybrid formulation (LDH–MTX) was freeze dried and was
named as sample B0.
To estimate the pH dependent chemical stability of MTX in
sample B compared to sample B0, study of in vitro dissolution
kinetics of the same was carried out at pH 7.4 using PBS
medium.Development of PLGA coating on LDH–MTX nanohybrid by
double emulsion (W1/O/W2)–solvent evaporation technique
Coating of LDH–MTX by PLGA (50 : 50) was done using a
double emulsion–solvent evaporation technique followed by
high pressure homogenization.30 An aqueous suspension
(5 ml) containing 300 mg of LDH–MTX (equivalent to 100 mg
of MTX present in sample B) was emulsied in 15 ml solution
of PLGA (0.6 g PLGA in 15 ml dichloromethane), using a high
speed homogenizer (IKA T25 ULTRA-TURRAX®, Germany)
@12 000 to 15 000 rpm. The resulting water-in-oil (W1/O)
emulsion was transferred into a specic volume (50 ml) of an
aqueous solution comprising 1% (w/v) poly(vinyl alcohol) used
as an emulsier.31 The mixture was further emulsied for 2
min by homogenization (@8000 rpm) to obtain a double
emulsion system. The solvent, dichloromethane was allowed
to evaporate slowly at room temperature for a period of 12 h
under agitation (@900 rpm) using a magnetic stirrer (IKA C-
MAG HS7, Germany). The resulting PLGA coated LDH–MTX
was collected by centrifugation at 8519g rcf (Heal Force, Neo-
fuge 15R, China) for 10 min and was washed several times with
decarbonated water followed by freeze drying (EYEL4,
FDU2200, Japan, at 82 C and 20 Pa pressure) to obtain a ne
powder. This was named as sample C. Each of the above
samples A, B and C were prepared in triplicate to check the
reproducibility of the results. The amount of methotrexate
present in sample B and C was quantied by HPLC analysis
(see eqn (S1) and (S2) in ESI†).Development of PLGA–MTX nanoparticles by single emulsion
(O/W)–solvent evaporation method
Briey, 200 mg of methotrexate and 400 mg of PLGA were dis-
solved in 5 ml acetone, and the resulting drug-polymeric39484 | RSC Adv., 2015, 5, 39482–39494solution was added slowly, drop by drop through a 16 gauge
needle in 15 ml of aqueous phase containing surfactant solu-
tion, poly(vinyl alcohol, 1% w/v) under high speed homogeni-
zation at 13 500 rpm for 5 min.32 The resulting O/W emulsion
formed as above was stirred for a period of 8 h for complete
evaporation of the solvent. The resulting suspension was
centrifuged at 8519g rcf for 15 min and washed several times
with decarbonated water. Finally, the particles were resus-
pended in a cryoprotectant (mannitol solution) and freeze dried
at 80 C for 12 h with a vacuum pressure of 20 Pa. This was
named as sample D. The amount of methotrexate present in
sample D was quantied by HPLC analysis (see eqn (S3) in
ESI†).In vitro dissolution study of sample B and B0
To estimate the time dependent degradation of the active drug
present in sample B and B0, intercalated under two diﬀerent pH
conditions, 7.00 and 8.5, respectively, known quantities of the
samples B and B0 (comprising methotrexate equivalent to 25 mg
of active drug via intravenous route in single dose for treatment
of cancer) were dispersed in 100 ml of phosphate buﬀer saline
(pH 7.4) and at specic time intervals 5 ml of aliquots were
withdrawn and replenished with the same. The aliquots were
collected and was ltered through the membrane lter as above
and were quantied using HPLC.In vitro drug release study of MTX from samples B, C and D
In vitro drug release of MTX from samples B, C and D were
carried out using type-II USP dissolution test apparatus (Elec-
trolab TDT-146 08LMumbai, India). In this, 0.086 g of sample B,
0.158 g of sample C (same as above) and 0.190 g of sample D
were placed in a dialysis tubing cellulose membrane bag (cut oﬀ
molecular weight 14 kD, M/s Sigma-Aldrich, St. Louis, MO
63178 USA) separately and immersed in 900 ml of PBS (pH 7.4)
maintained at 37.2 C with constant stirring@100 rpm.33 At
specic time intervals, 10 ml of aliquot was withdrawn and
replenished immediately. The aliquots were ltered using a
10 ml luer lock syringe (part no. 008962, SGE Analytical Science,
Victoria, Australia) with a 13 mm plastic Swinney lter holder
(part no. NR 013100, Pall Corporation, USA) through a 0.2 mm,
13 mm dia Nylon 66 lter paper (Pall Corporation, USA). The
ltered solution mentioned above was injected into the injec-
tion valve (injection volume: 10 ml) of the chromatograph (HPLC
820 Metrohm AG, Herisau, Switzerland). The retention time of
the MTX drug in the column was recorded against the absor-
bance of the same using the UV-VIS detector (Lambda1010
Bischoﬀ, Switzerland, wavelength range 190–800 nm). The
mobile phase used for the analysis was a mixture of tris buf-
fer : methanol : acetonitrile (80 : 10 : 10 v/v, pH 5.7), at ow rate
of 0.8 ml min1 at lmax 313 nm. Before the analysis as above, the
HPLC was calibrated using standard solutions of MTX in the
concentration range 10–100 ppm. The calibration curve was
generated with ve known concentrations of the drug as above
against its corresponding peak area derived from the chro-
matograms (Fig. 7A).This journal is © The Royal Society of Chemistry 2015
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View Article OnlineIn vitro bioassay
Cell culture. Colon cancer (HCT-116) cells were obtained
from ATCC (Rockville, MD, USA). All the cell lines were routinely
cultured in DMEM (Invitrogen, Carlsbad, USA) supplemented
with 10% heat-inactivated fetal bovine serum (Gibco, Invi-
trogen, UK), 2 mg ml1 sodium bicarbonate, 1 mg ml1 peni-
cillin G and 1 mg ml1 streptomycin, in 10 cm diameter plastic
Petri dishes at 37 C in a humidied atmosphere with 5% CO2
in an incubator (HF90 Heal Force, China). The cells were sub-
cultured using trypsin–EDTA when they were 90–95%
conuent.34 All experiments were done with the cells when they
were within seven passages aer revival from cryopreservation.Determination of IC50 of MTX on HCT-116 cell line
The IC50 of MTX was evaluated at diﬀerent concentrations in the
range 5–40 mg ml1 (ref. 35) with a stock solution of MTX (1 mg
ml1) in dimethyl sulfoxide (DMSO, GR grade, Merck, India). To
this, 1  104 HCT-116 cells per ml per well were plated in a 96-
well plate. The cells were then incubated at 37 C in the CO2
incubator for 24 h to allow suﬃcient cell adhesion, and the
incubation was continued for a total duration of 72 h aer
addition of MTX to the extent 5, 10, 15, 20, 25, 30, and 40 mg
ml1 (in triplicate). Cultured HCT-116 cells (1  104 cell per ml)
in DMEM medium was taken as control. Aer 72 h, the MTT
assay was performed by adding 10 ml of 3-(4,5-dimethylthiazole-
2-yl)-2,5-phenyltetrazolium bromide (MTT) reagent at 1 mg
ml1 (Sigma-Aldrich, USA), in 1 : 9 ratio (MTT reagent : DMEM
medium) to all the wells with subsequent incubation in dark for
a period of 4 h at 37 C. The reaction was stopped by adding
100 ml DMSO to each well of the plate aer removal of the MTT
and DMEM medium. The absorbance was then measured at
550 nm in an ELISA reader (Bio-Rad, USA), the dose response
curves were generated and the HCT-116 cell sensitivity to MTX
was expressed as IC50.Time dependent IC50 study of samples B, C and D
Briey, 10 000 cell per well were taken in a 96 well plate, aer 24
h incubation at 37 C in humidied atmosphere containing 5%
CO2, the cells as above were treated with methotrexate loaded
nanoparticles LDH–MTX, PLGA–MTX, PLGA–LDH–MTX, having
MTX concentration (21 mg ml1), for 24, 48, 72 and 96 h (ref. 36)
in the triplicate manner whereas cells which received 200 ml
culture medium containing 5% DMSO served as control. We
have carried out the study on half maximal inhibitory concen-
tration (IC50) of the active drug MTX loaded in three diﬀerent
samples, B, C and D upto an extended time point of 96 h, based
on the controlled and slow release of MTX from polymer coated
matrices (PLGA–LDH–MTX and PLGA–MTX) that indicates the
possibility of better eﬃcacy of the same in an extended time
period.
Next, the cell viability was measured by MTT assay, as
mentioned above and the absorbance of each well was read at
550 nm using ELISA reader (Bio-Rad, USA), to determine the
eﬃcacy of MTX in samples B, C and D respectively.This journal is © The Royal Society of Chemistry 2015Instruments and characterization
Particle morphology and size of the samples A, B, C and D were
examined by a Carl Zeiss SMT AG SUPRA 35VP (Germany) eld
emission scanning electron microscope (FESEM). The
elemental composition of the samples (data not shown here)
was studied using energy dispersive X-ray spectroscopy (EDX)
attached to the FESEM. Particle size, polydispersity index (PDI)
and zeta potential were measured using a Zetasizer Nano ZS (M/
s Malvern, Worcs, UK) based on quasi-elastic light scattering.
The samples were dispersed in deionized water and diluted 1/5
(v/v) with the same at room temperature. Zeta potential was
measured using the same instrument at 25 C following a 1/10
(v/v) dilution in deionised water. All the experiments as above
were repeated at least three times to check the reproducibility of
the results. Fourier-transform infrared spectra (FTIR) were
recorded in a spectrophotometer (Perkin-Elmer Frontier™ IR/
FIR, Waltham, USA) using KBr (M/s Sigma Aldrich, >99%
pure) pellet (sample: KBr 1 : 100 by weight) spectrometer in the
400–4000 cm1 range with average of 50 scans to improve the
signal to noise ratio. Thermo gravimetric analyses (TG-DTA) of
sample powders were carried out using a NETZSCH STA 409 CD
thermal analyzer. The tests were carried out from ambient
temperature to 1000 C at a heating rate 10 Cmin1 in nitrogen
atmosphere (ow rate 40 cm3 min1). The physical compati-
bility of MTX drug entrapped in the sample B and C was
determined by the diﬀerential scanning calorimetry (STA 449 F3
Jupiter®, NETZSCH, Germany). In this, 5 mg of MTX, PLGA,
sample B, sample C, physical mixture of MTX and sample A as
placebo nanoparticles (MTX: sample A in 1 : 1 ratio by weight)
were sealed in standard aluminum pans with lids and were
heated from ambient to 500 C (@5 C min1) in nitrogen
atmosphere.Results and discussion
The pristine LDH was prepared by coprecipitation of the
hydroxides of bivalent and trivalent metal ions at constant pH.37
In this, the metal hydroxide with lowest solubility will precipi-
tate out rst, e.g., Al(OH)3 in the present case, while Mg
2+ will
remain in solution, subsequently leading to the precipitation of
LDH as following:
2Mg2+ + Al3+ + 3OH/ Al(OH)3(s) + 2Mg
2+ (1)
2Mg2+ + Al(OH)3(s) + 3OH
/ [Mg2Al(OH)6]
+ (2)
In the above equations, water molecules are le out for
simplicity. A schematic representation of the above reactions is
shown below (Scheme 1).
The experimental yield of sample A was 16.7% sample B was
49.74%, for sample C was 67.03% and 76.6% in case of
sample D.
Fig. 1 depicts the FESEM images of sample A (LDH), sample
B (LDH–MTX) and sample C i.e. PLGA coated LDH–MTX. Panel
(a) shows cluster of ake/disk-shaped particles of size range
100–200 nm, distributed uniformly all over the sample in LDH.
Both (a) and (b) panels exhibit the cross section view of some ofRSC Adv., 2015, 5, 39482–39494 | 39485
Scheme 1 Intercalation of MTX drug within the interlayer space of
LDH, followed by coating of LDH–MTX using PLGA (50 : 50) exhibiting
spherical shape of the drug loaded nanoparticle.
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View Article Onlinethe particles (arrow marked) taking rod-like morphology for
both LDH and LDH–MTX. On incorporation of the drug MTX,
no major change could be noticed for the particle morphology
and size distribution, as evident from panel (b).
Panel (c) shows uniform distribution of agglomeration free
nanoparticles of PLGA polymer coated LDH–MTX, at low
magnication (Fig. 1). Almost all the particles here have globular
morphology, on being coated with PLGA. Nearly ve times
magnied image of a discrete PLGA coated particle as above in
panel (d) clearly depicts the globularmorphology and presence of
the encapsulated LDH–MTX nanocluster (arrow marked) within
the polymer coating. Additional images of the LDH–MTX aggre-
gates followed by formation of agglomeration free PLGA coated
LDH–MTX nanoparticles and PLGA coated MTX drug both at
lower and higher magnication are given in Fig. S1 in ESI.†
The particle size aﬀects the biopharmaceutical, physico-
chemical and drug release properties of the nanoparticles andFig. 1 FESEMmicrographs of (a) pristine LDH (sample A), (b) LDH–MTX
(sample B), (c) low magniﬁcation image of PLGA coated LDH–MTX
(sample C) showing globular morphology of the nanoparticles, and (d)
discrete globule shaped particles of PLGA coated LDH–MTX at higher
magniﬁcation showing the presence of LDH–MTX nanoparticles
within the polymer coating (arrow marked).
39486 | RSC Adv., 2015, 5, 39482–39494has direct relevance to the stability of the formulation. Smaller
particles tend to aggregate fast,38 thereby resulting in sedi-
mentation. The pristine LDH particles were smaller than the
MTX intercalated LDH nanoparticles which can be attributed to
the increase in the gallery height on intercalation of the MTX
drug in the interlayer space of LDH.
The pristine LDH and LDH–MTX nanoparticles exhibit
unimodal distribution of the size in the range 50–120 nm. The
D50 values of 60 nm and 80 nm of pristine LDH and LDH–MTX
respectively with the polydispersity index (PDI) of 0.2 are
indicative of a narrow distribution in the colloidal size range
that could not be obtained earlier39,40 and is attributed to an
eﬀective charge neutralization of the precipitated nanoparticles
at neutral pH condition of the medium. Hence, as evident,
majority of the drug loaded nanoparticles can reach the target
cells41,42 during drug delivery. Similar result on particle size
distribution is presented in ESI (Fig. S2†). The variation in the
colloidal stability, exhibited by the electrokinetic potential (z) in
the range 43.20 to 19.01 mV for LDH and LDH–MTX respec-
tively, as a function of surface charge, is indicative of interca-
lation of the anionic drug within the LDH interlayer, thereby,
neutralization of the cationic charge of the brucite layers of
LDH.43
Hence, the pristine LDH exhibits a good electrokinetic
stability (z ¼ 43.20 mV) in the colloidal suspension comprising
aggregation free nanoparticles in the cationic environment
whereas the same for LDH–MTX indicate incipient stability
(z ¼ 19.01 mV) on account of occulation of the nanoparticles
during the charge neutralization phenomenon as above. On
encapsulation of MTX drug in PLGA nanoparticle, the average
particle size was found to be in the range of 120–160 nm with
D50 of 140 nm (Fig. 2A, panel c), and a PDI of 0.23 whereas, in
case of LDH–MTX coated with PLGA, a unimodal size distri-
bution was obtained in the range 150–300 nm with D50 of 200
nm, and a PDI of 0.35. The electrokinetic potential of23.5 mV,
in the later case indicates an incipient stability and is due to the
presence of uncapped terminal carboxylic acid group of the
PLGA polymer chains in the coated LDH–MTX nanoparticles.44
The eﬀect of emulsier concentration in the process of emul-
sication is well known45 that in turn inuences both the
particle size and zeta potential of the PLGA coated LDH–MTX
nanoparticles, prepared by double emulsion–solvent evapora-
tion technique in the present case. Importantly, the optimized
concentration (Experimental section) of poly(vinyl alcohol),
used as nonionic emulsier here, plays a key role in masking
the anionic chain extremities of the PLGA polymer,46 (Scheme 2)
thereby reducing the nanoparticle occulation leading to a
narrow particle size distribution and formation of a stable
suspension as above. The diﬀerence in colours observed in layer
b and c (Fig. 2B) is due non-matching refractive indices between
LDH–MTX and PLGA polymer. See Table S1 of ESI† for detail
information about a few related parameters.
The stretching vibrations at 1405 and 1609 cm1 are attrib-
uted to C]C stretching of MTX, present in LDH–MTX in Fig. 3a.
The broad hump at 3458 cm1 in Fig. 3b is due to the stretching
vibration of both structural hydroxyl and interlayer water
molecules of the brucite layers.43 The bands of mediumThis journal is © The Royal Society of Chemistry 2015
Fig. 2 (A) Particle size distribution (intensity) of (a) pristine LDH (sample A) (b) LDH–MTX (sample B) (c) PLGA–MTX (sample C) and (d) PLGA
coated LDH–MTX (sample D) suspensions measured by dynamic light scattering technique. (B) Clear solution of MTX, showing transparent
yellow colour, (b) stable suspension of LDH–MTX, showing lemon yellow colour and (c) PLGA coated LDH–MTX suspension, showing faint
yellow colour. The solution/suspensions as above have been prepared at room temperature, using ultrapure water as medium.
Scheme 2 The role of poly(vinyl alcohol) in masking the anionic
terminal carboxylic groups of PLGA coating on LDH–MTX for a
moderate zeta potential of the system.
Fig. 3 FTIR spectra of (a) LDH–MTX (sample B), (b) sample A, (c) MTX,
(d) PLGA (50 : 50) (e) PLGA coated LDH–MTX and (f) PLGA–MTX.
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View Article Onlineintensity in the lower wave number region from 425 to
600 cm1, were due to M–O vibration and M–OH bending in the
brucite-like layers,40,43,47,48 while the presence of a strong band at
1392 cm1 signies the presence of NO3
 anions in pristine
LDH (Fig. 3b). The intensity of this band was reduced in LDH–
MTX (Fig. 3a arrow marked), suggesting MTX intercalation
leading to partial removal of NO3
 anion. This is in corrobo-
ration with the presence of symmetric and asymmetric
stretching vibration of COO (nCOO
) at 1380 and 1560 cm1,
respectively, exhibiting MTX intercalation, as above. Other
vibration bands of low and medium intensity are in line with
our previous works.39,40,43 The characteristics peak of MTX was
showed (Fig. 3c) at 3460 cm1 (–NH stretching), 1685 cm1
(COOH), 1659 cm1 (–CONH) and 850 cm1 (aromatic stretch).
Fig. 3d exhibits vibration bands of PLGA, due to stretching of
alkyl group (2850–3000 cm1), carbonyl –C]O stretching
(1700–1800 cm1), C–O stretching (1050–1250 cm1) and –OH
stretching (3200–3500 cm1).49 At 1755 cm1, the vibration
band of medium intensity is attributed to –C]O stretching
PLGA (Fig. 3, panel d) hydrocarbon chain, that remains unal-
tered in the spectrum corresponding to MTX and LDH–MTX
loaded PLGA nanoparticles, as has been indicated by an ellip-
tical shape in Fig. 3, panels d, e and f, indicating no chemicalThis journal is © The Royal Society of Chemistry 2015interaction/bonding between the PLGA coating and the encap-
sulatedMTX/LDH–MTX. In addition to this, the vibration bands
of low intensities corresponding to C]C stretching of MTX at
around 1609 cm1 is a good proof of the successful entrapment
of MTX in PLGA in both the samples C and D (panels e and f of
Fig. 3).
Fig. 4 shows the thermogravimetric curves (TG), carried out
on LDH, MTX and LDH–MTX under air purge (thermooxidative
analysis) condition. The hydrated pristine LDH powder shows a
loss of 45.27% of its mass on heating upto 1000 C. This loss
corresponds to three decomposition steps at 125 C, 250 C and
410 C, as is evident from the derivative plot of TG (Fig. 4A). The
rst decomposition step at 125 C is attributed to the removal of
surface adsorbed water molecules (13.75%), the second step
corresponds to dehydroxylation of the structural water and the
loosely bound exchangeable charge balancing anions that takes
place in the temperature range 200–250 C (8.6%). The
remaining weight loss of 23.36% at 410 C corresponds to the
dehydroxylation during spinellization from hexagonal LDH
moiety to an oxide lattice.39,40,43
The diﬀerential thermal analysis prole at panel (a) of
Fig. 4B, exhibits an endotherm at 410 C (ref. 43) correspondingRSC Adv., 2015, 5, 39482–39494 | 39487
Fig. 4 (A) Thermogravimetry (TG) plots of (a) pristine LDH (sample A) and (b) LDH–MTX (sample B) (c) MTX. The derivative of TG data for LDH is
shown as dotted line. (B) Diﬀerential thermal analyses of (a) pristine LDH (sample A) and (b) LDH–MTX (sample B).
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View Article Onlineto the decomposition of bound nitrate, carbonate ions and due
to dehydroxylation during spinellization as above.39,43 In case of
LDH–MTX, the DTA pattern shows a small hump at 254 C, that
may be attributed to dehydroxylation of hydrogen bonded
structural water. It indicates an enhanced thermal stability of
the entrapped MTX drug, as evident from the melting point of
bare MTX drug, in the range 195–210 C.50 The hump of
medium intensity at 535 C is attributed to the decreased strain
energy of MgO nanocrystals on decarboxylation and decompo-
sition of MTX drug in the interlayer space of LDH. The loading
of MTX in LDH–MTX is estimated analyzing the thermogravi-
metric data,51 as given below.
Let us assume 100 g of LDH–MTX contains ‘x’ g MTX of
which 3.86x/100 g will remain as residue aer heating to 1000
C and (100  x) g sample A of which 54.73(100  x)/100 g will
be residue on heating to 1000 C. So, 0.03863x + 4.73  0.5473x
¼ 38.58 (residue for LDH–MTX on heating to 1000 C) which
gives rise to ‘x’ as 32.3% MTX loading in LDH–MTX. The MTX
loading data as above corroborates the same obtained from the
HPLC analysis detailed in ESI,† to be 32 wt% approximately.
Importantly, the MTX loading obtained by thermogravimetric
analysis as above (data not shown here) for sample B0,51
prepared in sodium hydroxide medium at alkaline pH (Experi-
mental section) was 13.1% only. This may be attributed to the
alkaline hydrolysis of MTX drug at pH 8.5 that leads toFig. 5 Diﬀerential scanning calorimetry (DSC) of (a) MTX (API drug) (b) LDH
PLGA and (f) PLGA coated LDH–MTX.
39488 | RSC Adv., 2015, 5, 39482–39494formation of degradation by product of N10-methyl folic acid.9,10
In case of sample C and D, the drug loadings are 56.60 wt% and
14.20 wt% respectively, obtained from HPLC analysis, detailed
in ESI.†
Fig. 5 exhibits the diﬀerential scanning calorimetric (DSC)
data of methotrexate, LDH–MTX physical mixture in 1 : 1 ratio
by weight, LDH–MTX and LDH. Methotrexate thermogram in
panel (a) shows a broad endothermic peak at around 200 C,
due to fusion of the hydrated form of the pure drug.50 A minor
shi in the peak as above to around 196 C is observed in case of
the LDH, MTX physical mixture (Fig. 5b), indicating intact
physical state of the constituent compounds.
However, possibility of a weak interaction between MTX and
its nanocarrier LDH, at higher temperature cannot be ignored
here.51,52 In case of LDH–MTX, the absence of the above peak, at
panel (c) of Fig. 5, conrms the intercalation of methotrexate
drug in the LDH interlayer. In case of bare PLGA, an endotherm
at 220 C conrms its fusion point in the temperature range
220–230 C (ref. 53 and 54) whereas, on encapsulation of LDH–
MTX/MTX the same could not be obtained on account of dilu-
tion of PLGA in the PLGA coated MTX/LDH–MTX as the
composites contain less than 30% PLGA (TG(s) not shown here).
A medium intensity endotherm at 373 C corresponds decar-
boxylation during the spinellization process leading to nucle-
ation of magnesium aluminate spinels and thereby: MTX physical mixture 1 : 1 ratio (c) LDH–MTX and (d) LDH. DSC of (e)
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinetransformation of hexagonal LDH moiety to oxide spinels.39,40,43
We obtained similar results from the TG-DSC data shown in
panels (c) and (d) of Fig. 5 (arrow marked).
Fig. 6 demonstrates the time dependent (0.5 and 10 h here)
HPLC analysis of samples B and B0, where MTX was intercalated
in the LDH interlayer, under two diﬀerent pH conditions of 7.00
and 8.5.40,52 Initially, at 0.5 h, panel A exhibits the MTX
concentration of 7.7 ppm, having retention time of 6.6 min, for
sample B. In case of sample B0, at the same time point as above,
a small peak showing retention time of 5.3 min and concen-
tration 0.82 ppm, corresponds to N10-methyl folic acid, the
degradation by product of MTX (shown in Scheme 3), formed
due to specic hydroxide ion-catalyzed reaction of the dianionic
drug,9,10,55 during intercalation into LDH layers under alkaline
pH 8.5 condition, using 0.1 M sodium hydroxide solution. In
case of sample B, in panels A and C, no such peaks are observed,
on account of the maximum stability of MTX at pH 7.00, inFig. 6 Chromatograms showing the retention time in between 6.5–7.0 m
pH 7.4: panel A showing the absence of any degradation peak (N10-me
showing the presence of the peak as above for sample B0 (arrowmarked).
h of MTX release from sample B. Panel D showing the increased concen
showing the peak area of the degradation peaks of sample B0 at (a) 10 h an
methyl folic acid concentration against the peak area. The straight line thr
relevant parameters of the study as above.
This journal is © The Royal Society of Chemistry 2015ammonium acetate solution. Importantly, the concentration of
the degradation byproduct of MTX drug, N10-methyl folic acid,
increases substantially with time: nearly six times (from 0.82
ppm at 0.5 h to 4.85 ppm at 10 h), as shown in panels D and E, in
a period of nine and half hours (0.5 to 10 h) conrming the
continued degradation process. The chromatograms of the
intermediate time points (2, 4, 6 and 8 h) are demonstrated in
ESI (Fig. S3†) that in turn, corroborates the above observation.
Table S2 in ESI† has enlisted all the relevant parameters of the
Fig. S3,†mentioned as above. The solid line through the scatter
points is the linear t to the data, exhibited in panel F.
The in vitro drug release from the above nanoparticles was
studied by the dialysis membrane/bag diﬀusion technique. The
dialysis bag retained nanoparticles and allowed the diﬀusion of
drug immediately into the receiver compartment. The size of
the nanoparticle also aﬀect the drug release kinetics.56 In
Fig. 7B, layer (a) show complete (100%) release of MTX drug by ain for MTX release from LDH–MTX nanoformulation in PBS medium at
thyl folic acid) after 0.5 h of release of MTX from sample B. Panel B
Panel C showing the absence of any degradation peak as above after 10
tration of the degradation peak of sample B0 (arrow marked). Panel E
d (b) 0.5 h of MTX release. Panel F showing the calibration curve ofN10-
ough the scatter plot is linear ﬁt to the data. Table 1 demonstrates all the
RSC Adv., 2015, 5, 39482–39494 | 39489
Scheme 3 Hydrolysis of MTX to form N10-methyl folic acid in alkaline
pH condition.
RSC Advances Paper
Pu
bl
ish
ed
 o
n 
22
 A
pr
il 
20
15
. D
ow
nl
oa
de
d 
by
 F
re
ie
 U
ni
ve
rs
ita
et
 B
er
lin
 o
n 
04
/0
5/
20
15
 0
9:
34
:2
7.
 
View Article Onlineperiod of 2 h, due to absence of drug–carrier interaction in the
physical mixture. In case of sample B (LDH–MTX), layer (b)
shows the cumulative release in PBS at pH 7.4, which encom-
passes 99.7% of the drug by a period of 12 h. Of this, the release
of 33–35% of the drug by a period of 2 h accounts for the looselyFig. 7 (A) Calibration plot of methotrexate in phosphate buﬀer saline
(LDH : MTX in 1 : 1 ratio by weight) and (b) LDH–MTX. (sample B) (c) PLGA
of sample B. (C0) Zero order plot of sample D. (C00) Zero order plot of sa
39490 | RSC Adv., 2015, 5, 39482–39494bound surface adsorbed drug, that leads to its local accumula-
tion and hence, severe toxicity.57 The remaining 65% of the
release is attributed to the diﬀusion ofMTX from the interlayer of
LDH, by a fast anion exchange process in PBSmedium, as shown
in part A of Scheme 4. In case of sample D shown in layer (c)
release ofmethotrexate from the PLGA nanoparticles consisted of
two phases: phase 1 comprises the drug adsorbed on the surface
of the polymer nanoparticles, leading to an almost linear release
pattern whereas in phase 2, slow hydrolysis of the polymer in the
release medium leads to loosening of the polymer chain and
ultimately complete rupture of the same, as shown in step 2 and
20 of Scheme 4, part B, resulting in slow and continuous drug
diﬀusion through the pore, for a prolonged period of 120 h (5
days). In the present report, we have made an attempt to address
the ‘toxicity due to local accumulation’ issue of the nephrotoxic
drug MTX, as mentioned above, by imparting a thin polymer
layer on the LDH–MTX nanoparticles, as detailed in the ‘Experi-
mental section’. Interestingly, a substantial reduction (7 times)
in the initial release rate (<5% by a period of 2 h, Fig. 7B, layer (d))
could be achieved along with extension of the release period
approximately by two times compared to PLGA–MTX system and
by twenty times compared to LDH–MTX system without any
polymer coating. The possible mechanism for arrest of the
release as obtained above is speculated in the following sche-
matic hypothesis.
The polymer entrapped LDH–MTX (sample C),58,59 initially,
in contact with PBS at pH 7.4, hydrolysis of the PLGA matrix
results in the polymer chain relaxation slowly, leading to release
of the same in the dissolution medium. This immediately leads
to anion exchange of the drug molecules with the phosphateat pH 7.4. (B) Cumulative release proﬁles of MTX (a) physical mixture
–MTX. (sample D) and (d) PLGA–LDH–MTX (sample C). (C) Higuchi plot
mple C.
This journal is © The Royal Society of Chemistry 2015
Scheme 4 Possible hypothesis of release of MTX from three diﬀerent matrices of samples B, C and D.
Table 1 Variation in concentration and peak area, versus the retention
time of the samples B and B0 as a result of in vitro dissolution study, at
the time points, 0.5 and 10 h
Concentration
(ppm) Peak area (mV s)
Retention time
(min)
30 min 10 h 30 min 10 h 30 min 10 h
(a) Methotrexate
Sample B 7.7 28.5 470.88 1962.3 6.6 6.85
Sample B0 3.7 25.4 230.77 1584.8 7.1 6.78
(b) N10-methyl folic acid
Sample B0 0.82 4.85 2.9 7.1 5.3 5.2
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View Article Onlineions of the PBS medium, as shown in step 3 and 30of part C,
Scheme 4 which is considered as phase 1 of the release, upto
a period of 75–80 h, encompassing 90% of the release,
exhibiting superior performance of the system by its slow and
controlled release prole, compared to PLGA–MTX in the time
frame of 0 to 70 h. In phase 2 of the release, complete rupture of
the polymer matrix, as shown in step 300 of part C, Scheme 4,
results in release of the remaining LDH–MTX units into the
dissolutionmedium, followed by anion exchange phenomenon,
as mentioned above. This part encompasses the remaining
9.5% of the release, upto a period of 160 h.
The analogy of various steps that have possibly taken place in
the in vitro drug (MTX) release process of three diﬀerent
samples, B, C and D has been indicated in the obtained
cumulative release prole, as shown in part D of Scheme 4, by
the numericals, corresponding to the steps in Scheme 4.
The obtained in vitro release data as above were tted in the
release kinetic models: zero order, rst order, Higuchi's square
root plot, and Korsmeyer–Peppas60–63 and the corresponding
correlation coeﬃcients and the kinetic exponents are presented
in Table 2. Importantly, for sample B or LDH–MTX system, theThis journal is © The Royal Society of Chemistry 2015Higuchi model of release is proposed based on the obtained
R2 value (0.9996), (Fig. 7C) indicating diﬀusion controlled
release. In case of sample D and sample C, the same complies to
zero order release model (R2 ¼ 0.9981 and 0.9934 respectively)
which conrm the controlled release phenomenon that is
independent of the drug concentration (Fig. 7C0 and C00).RSC Adv., 2015, 5, 39482–39494 | 39491
Table 2 Correlation coeﬃcients (R2) of diﬀerent model of release kinetics of (LDH–MTX, PLGA–MTX and PLGA–LDH–MTX)
Formulation Zero order First order Higuchi Korsmeyer–Peppas n values
LDH–MTX 0.9815 0.9991 0.9996 0.9914 0.382
PLGA–MTX 0.9981 0.9590 0.9657 0.9940 0.931
PLGA–LDH–MTX 0.9934 0.9917 0.9510 0.9910 0.948
Fig. 8 (A) The half maximal inhibitory concentration (IC50) of MTX using human colon tumour (HCT)-116 cell line. (B) Cell viability of samples B, C
and D, alongwith MTX, LDH and PLGA nanoparticles.
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View Article OnlineAdditional tting plots of the drug release kinetics model are
shown in Fig. S4 of ESI.†
The kinetic exponent ‘n’ for sample B (0.382) indicates the
release following Fickian diﬀusion phenomenon, whereas the
same for sample C and D systems are non-Fickian in nature.
This is on account of an anomalous mechanism, in which the
entrapped drug diﬀusion process is comparable to the relaxa-
tion rate of the polymer chain.64–66
Half maximal inhibitory concentration (IC50) of MTX and in
vitro cell viability assay of LDH–MTX, PLGA–MTX, PLGA–
LDH–MTX
The IC50 of the MTX drug used in this study was determined to
estimate the quantitative measure/concentration of the same to
inhibit a given biological process by half. This can directly be
correlated to the antagonist drug potency in the area of appli-
cation. As per the result shown in Fig. 8 part A, the IC50 value of
21 mg ml1 of MTX drug displayed a signicant dose-dependent
prole, aer 72 h incubation. Considering the above concen-
tration of methotrexate to attain the IC50 value, the cell viability
assay of samples B, C and D were performed at four diﬀerent
time points, 24 h, 48 h, 72 h and 96 h and the result is shown in
Fig. 8 part B. The time point 96 h was considered in our work,
based on the controlled and slow release of MTX from polymer
coated matrices (PLGA–LDH–MTX and PLGA–MTX) that indi-
cates the possibility of better eﬃcacy of the drug delivery system
in an extended time period.
In a period of 48 h, the LDH–MTX nanoparticles inhibit the
proliferation of 50% of the cells, compared to the same by a
period of 72 h, in case of bare MTX drug. This can be attributed
to the particle size alongwith the surface charge that leads to39492 | RSC Adv., 2015, 5, 39482–39494high aﬃnity of the drug loaded nanoparticles and easy cellular
uptake through the anionic cell membrane, by endocytosis
mechanism. In case of polymer encapsulated MTX (PLGA–
MTX), a similar eﬀect (58% inhibition) as LDH–MTX is
observed, compared to 56% in case of PLGA–LDH–MTX, in 72 h.
This may be attributed to the slow release rate of methotrexate
from the polymer matrices by chain relaxation and diﬀusion
mechanism in both the cases. Interestingly, in a period of 96 h,
the release of MTX at a continuous and controlled rate led to an
excellent inhibitory eﬃciency both for PLGA–MTX and PLGA–
LDH–MTX, compared to LDH–MTX and the bare drug, on
account of intracellular drug accumulation as above, over a
prolonged period of time. Finally, the biocompatible and
biodegradable nanoceramic carrier, LDH and the polymer
matrix PLGA are non toxic and can be completely metabo-
lized,67,68 hence, has no eﬀect on the cell viability, as shown in
Fig. 8 part B.Conclusion
The present work demonstrates the pH dependent chemical
stability of antineoplastic drug, methotrexate under two
diﬀerent pH conditions of 7.00 and 8.5, at which the dissolu-
tion of the drug was carried out using 0.3 M ammonium
acetate and 0.1 M sodium hydroxide solutions respectively, for
intercalation within the interlayer space of LDH. Interestingly,
the in vitro dissolution study of the samples at the time points
0.5, 2, 4, 6, 8 and 10 h as above revealed the peaks corre-
sponding to N10-methyl folic acid, formed by alkaline hydro-
lysis of methotrexate, in the later case which was not obtained
in the former case on account of the maximum stability of theThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinedrug at neutral pH condition (pH 7.00). Further, in case
of LDH–MTX, the drug loading at pH 7.00 is >two times
(32.3 wt% here) and for PLGA–LDH–MTX, it is >four times
compared to the case undertaken at alkaline pH condition
(13.1 wt%). The LDH–MTX nanoparticles have been coated
with PLGA to arrest the initial burst release (33–35% by a
period of 2 h), that leads to dose dumping at the site and
thereby to reduce the toxicity due to its local accumulation. To
establish novelty of the present approach, we developed PLGA
coating on MTX drug by single emulsion–solvent evaporation
technique, as well. Signicantly, we obtained a two times
extension of release of the drug in a controlled manner in case
of PLGA–LDH–MTX (99.5% release in 10 days), compared to
PLGA–MTX system (99.9% release in 5 days) explained on the
basis of a schematic hypothesis. This extended release
phenomenon of the PLGA–LDH–MTX for a period of 10 days
helps to minimize the dosage frequency (via intravenous route
in cycles within a single day) of HDMTX in cancer treatment,
thereby, helps to get rid of the painful procedure of chemo-
therapy, alongwith its side eﬀects and thus enhances patient
compliance to a great extent. In general, a particle size
distribution in the range 50–120 nm was obtained for LDH–
MTX whereas, on coating with PLGA, the same was in the
range 150–300 nm, indicating the possibility of reaching the
target cells, in both the cases. FTIR analysis indicates partial
reduction of the vibration frequency corresponding to the
nitrate anion, on insertion of the drug macromolecule in the
octahedral framework of LDH, followed by almost no shi in
the characteristic vibration frequencies of PLGA, exhibiting
absolute compatibility and no chemical interaction of the
same with the coated MTX/LDH–MTX. This data corroborates
with our DSC result which exhibits formation of an integrated
drug delivery system, on coating of LDH–MTX nanohybrid
particles with PLGA. The half maximal inhibitory concentra-
tion (IC50) of the MTX drug, obtained as gi sample was 21.13
mg ml1 on human colon tumour cells and the same for the
LDH–MTX systems with/without PLGA coating, showed the
eﬃcacy in the order, LDH–MTX > PLGA–MTX > PLGA–LDH–
MTX in a period of 48 h, whereas, importantly, in a longer time
gap of 48 h more, the order as above changes as, PLGA–LDH–
MTX > PLGA–MTX > LDH–MTX (96 h). In summary, the
present report elaborates the importance of neutral pH (7.00)
condition for obtaining chemically stable antineoplastic drug
MTX within the interlayer space of nanoceramic carrier, LDH,
with better loading, as mentioned above, compared to our
earlier reports. Further, the suitability of a biocompatible and
biodegradable polymer (PLGA here) coating on the nano-
ceramic based (LDH–MTX) drug delivery system to arrest the
initial burst release and extend the same in a controlled
manner has been illustrated by a schematic hypothesis. The
superiority of the PLGA–LDH–MTX system has been estab-
lished compared to its polymer coated counterpart, i.e., PLGA–
MTX system, w.r.t the drug loading (% by wt) and release
prole, and the work is primarily oriented to minimize the
dosage frequency of extremely toxic MTX drug in cancer
treatment and thereby improve patient compliance to a great
extent.This journal is © The Royal Society of Chemistry 2015Acknowledgements
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